trial · primary record
Selinexor
Endometrial Cancer
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 257 |
| Primary completion | 2028-01 |
| Primary endpoint | Investigator assessed Progression Free Survival (PFS) per RECIST v1.1 |
| Registry ID | NCT05611931 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:35:13.438Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05611931
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.